Literature DB >> 12844137

Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.

Ryoko Yoshida1, Miki Nakajima, Kiyoko Nishimura, Shogo Tokudome, Jun-Tack Kwon, Tsuyoshi Yokoi.   

Abstract

Cytochrome P450 (CYP) 2A6 catalyzes nicotine C-oxidation, leading to cotinine formation, a major metabolic pathway of nicotine in humans. There are genetic polymorphisms in the human CYP2A6 gene. Previously, we demonstrated that in vivo nicotine metabolism is impaired with the CYP2A6*4, CYP2A6*7, and CYP2A6*10 alleles in Japanese subjects and Korean subjects. An allele possessing a point mutation in the TATA box termed CYP2A6*9 (T-48G) has been reported to decrease the transcriptional activity in vitro as assessed by luciferase assay. In this study we investigated the effects of the CYP2A6*9 allele on in vivo enzymatic activity by evaluating nicotine metabolism. The mutation of T-48G was found only on the CYP2A6*1A allele but not on the CYP2A6*1B allele. Allele frequencies of CYP2A6*9 in Japanese subjects (n = 92) and Korean subjects (n = 209) were 21.3% and 22.3%, respectively. In Korean subjects the cotinine/nicotine ratios as an index of nicotine metabolism in the subjects with CYP2A6*9/CYP2A6*9 (4.3 +/- 2.4) were significantly lower than those in the subjects with CYP2A6*1A/CYP2A6*9 (7.7 +/- 5.6) and CYP2A6*1A/CYP2A6*1A (10.4 +/- 9.2) (P <.05 and P <.005, respectively). In Japanese subjects a similar result was observed, although it was not significant. Thus it is suggested that the mutation in the TATA box (CYP2A6*9 allele) caused the decreased in vivo enzymatic activity. With an in vitro study, it was shown that the expression levels of CYP2A6 messenger ribonucleic acid and coumarin 7-hydroxylase activity in human livers genotyped as CYP2A6*1/CYP2A6*9 and CYP2A6*9/CYP2A6*9 tended to be lower than those in human livers genotyped as CYP2A6*1/CYP2A6*1, although there was no significant difference because of the small number of samples. These in vitro data supported the in vivo data demonstrating that the CYP2A6*9 allele caused the decreased expression level and enzymatic activity of CYP2A6.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844137     DOI: 10.1016/S0009-9236(03)00090-0

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.

Authors:  Koji Takeda
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

3.  Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.

Authors:  J O'Loughlin; G Paradis; W Kim; J DiFranza; G Meshefedjian; E McMillan-Davey; S Wong; J Hanley; R F Tyndale
Journal:  Tob Control       Date:  2004-12       Impact factor: 7.552

4.  A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Xiaochun Zhang; Sandra A McDonald; Sharon E Murphy; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

5.  Associations of CYP2A6 genotype with smoking behaviors in southern China.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Qian Zhou; Peng Ding; Yan-Hui He; Xue-Qing Yu; Wei Chen; Casey Crump; Xiao-Zhong Wen; Wei-Qing Chen
Journal:  Addiction       Date:  2011-05       Impact factor: 6.526

6.  High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.

Authors:  Maxwell Afari Gyamfi; Masaki Fujieda; Kazuma Kiyotani; Hiroshi Yamazaki; Tetsuya Kamataki
Journal:  Eur J Clin Pharmacol       Date:  2005-01-20       Impact factor: 2.953

7.  The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.

Authors:  A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

8.  CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.

Authors:  Wiratchanee Mahavorasirikul; Wichittra Tassaneeyakul; Soisagwan Satarug; Ronnatrai Reungweerayut; Chacrin Na-Bangchang; Kesara Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

9.  Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.

Authors:  Eric C K Siu; Dieter B Wildenauer; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2006-01-28       Impact factor: 4.530

10.  Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.

Authors:  Hei-Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Sung Hoon Noh; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Jpn J Clin Oncol       Date:  2009-10-31       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.